SLC9A1 and arterial disorder: The robust experimental data demonstrating substantive cardioprotectiveproperties of NHE1 inhibitors, unmatched by other cardioprotective strategies,rapidly progressed to clinical evaluation of NHE1 inhibitors in patients withcoronary artery disease, mostly employing cariporide as the drug of choice.